Viruses Outpacing Drugs in Pandemic Fight
A recent international report has revealed an increasing gap between the rapid spread of dangerous viruses and the world's ability to develop effective antiviral drugs. The report shows a shortage in the drug pipeline, noting that out of 14 high-risk viral families, only 6 have indicators of therapeutic candidates in clinical trial stages, while there are no approved or advanced-stage compounds for three of these families. Additionally, the development of broad-spectrum antivirals capable of targeting multiple viruses within the same family remains in its early phases, extending the time gap to 4-5 years. The report emphasizes the importance of building up a stockpile of treatments and advancing broad-spectrum antivirals to better respond to pandemics before they escalate into widespread outbreaks, especially as diseases like Ebola and dengue continue to spread.
Notice: This Is an AI-Generated Summary
Comments (0)